Coreline Soft, a leading developer of medical artificial intelligence (AI) solutions, announced on July 8 that its AI-based coronary artery calcification (CAC) analysis software, ‘AVIEW CAC,’ has been designated as an innovative product by the Ministry of Science and Technology Information and Communication (MSIT).
The Innovative Product Designation System aims to accelerate private sector technological advancements by integrating public procurement with R&D policy. Only products derived from completed national R&D projects that demonstrate technological innovation through rigorous review are recognized as innovative products. This designation is intended to expedite the supply of validated, innovative technologies to the public procurement market, thereby promoting wider adoption within the public sector.
AVIEW CAC, now recognized as an innovative product, is a software that automatically quantifies coronary artery calcium scores from a single low-dose chest CT scan. This enables preemptive risk assessment of cardiovascular diseases. The software has received Class 3 medical device approval from the South Korean Ministry of Food and Drug Safety (MFDS), confirming its technical sophistication and safety standards in medical AI diagnostics. Its performance was published in the Journal of the American College of Cardiology (JACC), highlighting its clinical efficacy. Additionally, AVIEW CAC has obtained FDA 510(k) clearance in the United States, and is capable of quantitatively analyzing coronary calcification from chest CT scans acquired without cardiac gating.
Following this designation, Coreline Soft will be able to supply AVIEW CAC directly to public institutions through single-source contracts over the next three years. The product will also be prioritized in the government-wide pilot purchase program for innovative products. Kim Jin-guk, CEO of Coreline Soft, stated, “The designation of AVIEW CAC as an innovative product marks not just technological recognition but also a milestone in leading public innovation in early cardiovascular disease diagnosis. Going forward, we aim to advance AI diagnostic platforms for multi-disease detection—including lung cancer, cerebral hemorrhage, and cardiovascular conditions—and enhance clinical efficiencies and treatment quality across both public and private healthcare sectors.”
Since 2017, Coreline Soft has operated a successful AI-based lung cancer screening support and quality management solution, collaborating with over 80 institutions in the National Cancer Screening Program. This initiative has been recognized as a model integration of medical data management and precise AI diagnostics. The company has also secured a competitive edge in launching prominent lung cancer screening projects across European countries.
Recently, Coreline Soft was selected as a final implementer for the ‘AI-based Medical System Digital Transformation Support Project,’ a two-year initiative with a total budget of approximately 2.32 billion KRW. This project facilitated the creation of Korea’s first ‘4-in-1’ chest AI diagnostic platform within a public medical institution and successfully integrated the platform into the public healthcare network.
